Protagonist Therapeutics Inc annual ebitda for fiscal 2025 was -$128 million, compared with $280 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | ($128M) | $280M | ($76M) | ($128M) | ($123M) | ($64M) | ($77M) | ($42M) | ($37M) | ($32M) | ($15M) | ($9M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $3M | ($43M) | ($39M) | ($34M) | ($11M) | $134M | ($33M) | ($30M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PTGX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All PTGX financial statements → Interactive PTGX charts →
About TickerBase · Data methodology & sources · Privacy · Terms